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 INTRODUCTION 
 Cervical cancer, the second leading cause of cancer deaths 
in women worldwide, is associated to persistent infection of 
the cervical epithelium by high-risk type human papilloma-
viruses (HPV), most often type 16. 1 The recently introduced 
prophylactic vaccines against specific HPV types are highly 
effective in preventing persistent infections and precancerous 
lesions; however, they do not induce regression of established 
lesions. 2 As expression of E6 and E7 HPV oncogenes in cervi-
cal epithelial cells is required for the maintenance of the can-
cerous phenotype, they represent attractive target antigens for 
therapy. Therapeutic HPV vaccines designed to induce spe-
cific cytotoxic T-lymphocyte (CTL) responses against tumor 
cells have shown impressive results in animal models. How-
ever, their application in humans has shown modest clinical 
effectiveness, at best. More than 40 therapeutic vaccination 
trials (phase I, II, or II / III) against high-risk HPV encompass-
ing a total of 1,830 patients have either been published or are 
still ongoing (reviewed in ref.  3). To date, no candidate vaccine 
has demonstrated sufficient efficacy in inducing regression of 
HPV-induced cervical intraepithelial neoplasia or cancer to 
warrant commercialization. 
 In general, persistent HPV infection and cervical intra-
epithelial neoplasias do not promote inflammation. Therefore, 
we hypothesized that a limiting factor in the efficacy of thera-
peutic HPV vaccines to date is the inefficient recruitment of the 
systemic cell-mediated immune responses they induce to the 
local mucosal site of the neoplasia. In an attempt to increase tar-
geting of the vaccine-specific immune responses to the genital 
mucosa (GM), we have here evaluated local application of two 
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TLR agonists (CpG-ODN (CpG, a TLR9 agonist) or poly (I:C) 
(PIC, a TLR3 agonist)) after parenteral vaccination. In addi-
tion to their action as adjuvants, 4 these TLR ligands are known 
to modify the expression of selectins, integrins, chemokines, 
and chemokine receptors, 5,6 which may affect T-cell migra-
tion to effector sites. 7 Most TLR are expressed by the epithelial 
cells in the reproductive tract of women 8 and mice, 9 and in 
the latter, local vaginal production of chemokines was shown 
after intravaginal (IVAG) administration of TLR3 and TLR9 
agonists. 10 
 We recently showed that parenteral vaccination with an adju-
vanted HPV16-E7 polypeptide was able to induce E7-specific 
CD8 T cells in the GM of mice 11 and regression of small genital 
tumors in a novel orthotopic murine model for cervical can-
cer. 12,13 However, vaccination alone failed to induce regression 
of larger genital tumors. In the present study, we examined the 
possibility that IVAG administration of CpG or PIC following 
parenteral HPV-16 E7 vaccination could increase local vaccine-
specific CD8 T-cell number and improve the rates of genital 
tumor regression. 
 RESULTS 
 IVAG application of CpG or PIC after a subcutaneous (s.c.) 
E7 vaccination increased both E7-specific and total 
CD8 T cells in the cervix-vagina (CV) 
 We first examined whether IVAG CpG or PIC influences T-cell 
migration to the CV. Before IVAG treatment, C57BL / 6 mice were 
synchronized in a diestrus-like status to avoid possible variations 
in the IVAG immunostimulatory activity along the menstrual 
cycle. Groups of mice were IVAG instilled with phosphate-
buffered saline (PBS), CpG, or PIC, and three days later CV 
cells were analyzed by flow cytometry as depicted in  Figure 1a . 
CD8 T cells in CV were significantly increased after CpG or 
PIC instillation (mean percentage  ± s.e.m. of 0.31 ± 0.06,  P  <  0.05 
and 0.46 ± 0.10,  P  <  0.001, respectively), as compared with PBS 
(0.10 ± 0.02,  Figure 1b ), while CD4 T cells were not significantly 
affected (0.46 ± 0.05 and 0.44 ± 0.11, respectively) as compared 
with PBS (0.27 ± 0.04, see  Figure 1c ). Thus IVAG application of 
either CpG or PIC mainly resulted in attraction of CD8 T cells 
in CV. 
 We then reasoned that to attract E7-specific CD8 T cells in 
the GM, it was necessary to first induce an E7-specific response 
by vaccination before IVAG application of CpG or PIC. Groups 
of mice were s.c. immunized with a long synthetic E7 peptide 
together with adjuvants, 11 and 5 days later PBS (as control), 
CpG, or PIC was administered IVAG. Mice were killed at day 
9, and cells recovered from CV were stained with TetE7 (based 
on the well-known H-2Db-restricted E7 49 – 57 CTL peptide) or 
TetL1 (based on the irrelevant HPV16 L1 165 – 173 CTL epitope, 
as negative control) and anti-CD8 antibodies (see  Figure 2a , 
for representative E7-immunized mice IVAG administered with 
PBS, CpG, or PIC). The percentage of TetE7   +   CD8   +   cells in the 
CV of E7-vaccinated mice ( Figure 2b ) that had received IVAG 
CpG or PIC (0.59 ± 0.11 and 0.48 ± 0.09, respectively) was higher 
than in those that had received IVAG PBS (0.07 ± 0.01,  P  <  0.01, 
and  P  <  0.05 as compared with CpG and PIC, respectively). 
A similar  ~ fivefold increase in total CD8 T cells in CV of the 
same mice was also observed after the IVAG CpG or PIC treat-
ment ( Figure 2c , 3.16 ± 0.56 and 2.26 ± 0.41 as compared with 
PBS: 0.43 ± 0.04,  P  <  0.01 and  P  <  0.05, respectively), which 
resulted in similar percentages of TetE7   +   CD8   +   among the 
CD8   +   cells (ca. 18 % ,  Figure 2d ) in all mice. This finding, as well 
as the most unlikely presence of E7 antigen in CV, argues against 
local proliferation of E7-specific CD8 T cells. In addition and 
interestingly, the percentage of total CD4 T cells in CV ( Figure 
2e and f ) was not significantly modified by the IVAG CpG or PIC 
treatments. Together these observations suggest that IVAG CpG 
or PIC treatment after vaccination preferentially promotes the 
recruitment of CD8 T cells (and among these, E7-specific CD8 
T cells) from the periphery in CV, while total or E7-specific CD8 
T-cell responses in spleen or genital lymph nodes (GLNs) were 
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 Figure 1   Increase of total CD8 or CD4 T cells in cervix-vagina (CV) 
upon intravaginal (IVAG) CpG or PIC. Groups of C57BL / 6 mice were 
IVAG instilled with phosphate-buffered saline (PBS), CpG, or PIC, and 
3 days later cells recovered from single or pools of two CV were stained 
with CD8 – APC antibodies and CD4 – FITC antibodies, and analyzed by 
flow cytometry. A representative result for each group of mice is shown in 
( a ). Percentage of total CD8 T cells ( b ) and total CD4 T cells ( c ) within the 
recovered CV cells are shown for each IVAG treatment. The horizontal 
bars represent the mean percentages. Significant differences are 
indicated by  * for  P  <  0.05 and  * * * for  P  <  0.001. 
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not significantly affected ( Table 1 ). Although CpG and PIC act 
through different intracellular pathways (discussed below), com-
bining both molecules in IVAG application after vaccination did 
not have a synergistic effect, as specific and total CD8 (0.69 ± 0.11 
and 3.45 ± 0.66, respectively) or CD4 T cells (0.96 ± 0.20) did not 
significantly differ from those observed after IVAG application 
of a single TLR agonist. 
 Increased E7-specific CD8 T-cell responses in CV upon IVAG 
PIC application after an E7 vaccination is mediated through 
either TLR3 or Mda5 signaling pathways 
 As the particular activity of PIC observed in our experiments 
was not previously reported, we examined whether it is mediated 
by the well-documented signaling pathways. PIC is specifically 
sensed by TLR3 in the endosome, initiating signaling through 
the adaptor, Toll / IL-1R domain-containing adaptor inducing 
interferon (IFN)-  (Trif). 14 In addition, a TLR3-independent 
cytoplasmic pathway uses melanoma differentiation-associated 
gene 5 (Mda5), an RNA helicase 15 that depends exclusively on 
the CARD adaptor inducing IFN-  (Cardif). 16 We therefore 
tested PIC as an IVAG immunostimulant after E7 vaccination 
in Trif knockout (KO), Cardif KO, or Trif-Cardif double-KO 
mice. For this purpose, groups of KO mice were immunized 
with the adjuvanted E7 vaccine and IVAG administered 5 days 
later with PIC, PBS, or CpG (used in this case as a positive 
control that should not be affected by the gene deletions). A 
significantly increased percentage of both TetE7   +   CD8   +   cells 
and total CD8   +   cells in the CV of IVAG PIC-treated E7-vac-
cinated Trif KO mice (0.16 ± 0.03 and 0.98 ± 0.15, see  Figure 3a 
and b , left panels, respectively) was observed as compared with 
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 Figure 2   Intravaginal (IVAG) CpG or PIC administered after E7 immunization increased E7-specific and total CD8 T cells in cervix-vagina (CV). 
Groups of mice were subcutaneously immunized with the adjuvanted E7 vaccine and 5 days later IVAG instilled with phosphate-buffered saline (PBS), 
CpG, or PIC. Mice were killed 3 days later, at day 9, and cells recovered from pools of two CV were stained with CD8 – APC antibodies, CD4 – FITC 
antibodies, and TetE7 49 – 57 -PE or TetL1 165 – 173 -PE (as control). A representative result for CD8 and tetramer T-cell staining ( a ) or CD4 T-cell staining ( e ) 
for each group of mice is shown. The percentages of TetE7   +   CD8   +   cells ( b ), total CD8 T cells ( c ), TetE7   +   CD8   +   among the total CD8 T cells ( d ), and 
total CD4 T cells ( f ) within the recovered CV cells are shown for each IVAG treatment. The horizontal bars represent the mean percentages. Significant 
differences are indicated by  * P  <  0.05 and  * * P  <  0.01. 
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IVAG PBS-treated mice (0.03 ± 0.01,  P  <  0.05 and 0.24 ± 0.06, 
 P  <  0.001), corresponding to the ca. fivefold increase measured 
in the wild-type mice ( Figure 2b and c ). This suggests that PIC 
may also be recognized by other pathways than TLR3 in the 
GM. IVAG CpG in these mice induced an even higher increased 
percentage of both TetE7   +   CD8   +   cells and total CD8   +   cells in 
CV (0.29 ± 0.04 and 1.77 ± 0.20, respectively) as compared with 
E7-vaccinated Trif KO mice, challenged with PIC ( P  <  0.05 and 
 P  <  0.01, respectively). E7-specific and total CD8 T-cell percent-
ages were, however, similar in the spleen of all these mice (see 
 Supplementary Figure S1 , left panels) but somewhat lower than 
those observed in wild-type mice ( Table 1 ), suggesting that Trif 
signaling might have a modest role in the induction of a systemic 
CD8  +  response by our vaccine. 
 Surprisingly, in Cardif KO mice a significantly increased 
percentage of both TetE7   +   CD8   +   cells and total CD8   +   cells in 
CV was also observed in E7-vaccinated mice upon IVAG PIC 
treatment (0.69 ± 0.13 and 4.73 ± 1.00) as compared with IVAG 
PBS (0.06 ± 0.02 and 0.48 ± 0.09, respectively,  P  <  0.01 for both 
comparisons, see  Figure 3a and b , middle panels). This ca. 
10-fold increase is also observed when IVAG CpG was given to 
these mice (0.72 ± 0.09 and 4.61 ± 0.50, respectively). This dem-
onstrates that IVAG PIC does not strictly act through Mda5 in 
the CV of mice. Only in E7-vaccinated Trif-Cardif double-KO 
mice was IVAG PIC unable to increase the percentages of either 
E7-specific or total CD8 T cells in their CV (0.13 ± 0.02 and 
0.79 ± 0.13, respectively) as compared with IVAG PBS-treated 
mice (0.12 ± 0.02 and 0.90 ± 0.21, respectively, see  Figure 3a 
and b , right panels). In contrast, and as expected, IVAG CpG 
treatment was effective in these mice increasing both TetE7   +  
CD8   +   cells and total CD8   +   cells in CV (0.64 ± 0.13 and 3.58 ± 0.45, 
and  P  <  0.01 and  P  <  0.001, respectively, as compared with either 
 Table 1  Percentage of total TetE7   +   CD8   +   and CD8   +   cells in the spleen and GLN of E7-vaccinated mice IVAG challenged with 
different immunostimulants 
  Spleen  GLN 
 IVAG immunostimulant 
 Tet E7   +    CD8   +    
(mean percentage ± s.e.m.) 
 CD8   +    (mean 
percentage ± s.e.m.) 
 Tet E7   +    CD8   +    
(mean percentage ± s.e.m.) 
 CD8   +    (mean 
percentage ± s.e.m.) 
 PBS  0.65 ± 0.09 (10) a  12.26 ± 0.96 (10)  0.18 ± 0.05 (10)  18.33 ± 0.65 (10) 
 CpG  0.74 ± 0.17 (7)  10.18 ± 0.79 (7)  0.21 ± 0.07 (7)  18.04 ± 0.98 (7) 
 PIC  0.49 ± 0.06 (4)  10.05 ± 1.22 (4)  0.15 ± 0.02 (4)  18.79 ± 0.44 (4) 
 Abbreviations: IVAG, intravaginal; GLN, genital lymph node; PBS, phosphate-buffered saline. 
 a The number of mice in each group is indicated in parenthesis. 
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IVAG PBS- or PIC-treated mice). Taken together, these three 
experiments demonstrate that PIC is sensed by either TLR3 or 
Mda5 when administered IVAG and, somewhat unexpectedly, 
that no synergistic effect in CD8 T-cell recruitment seems to be 
induced when both signaling pathways can be activated. 
 Successive IVAG CpG applications after E7 vaccination 
induced increased and sustained E7-specific IFN-  -secreting 
cells in CV 
 As CpG is used as adjuvant in our E7 vaccine, it was not possible 
to use TLR9 KO mice to assess whether preferential recruitment 
of CD8 T cells after IVAG CpG in our setting was also mediated 
through the well-described TLR9 signaling pathway. 17 Instead, 
we took advantage of control ODNs with the same nucleotide 
sequence but lacking CpG, which cannot stimulate TLR9, 18 and 
examined how their activity would compare with CpG in our 
experiments. In addition, we used  ex vivo IFN-  ELISPOT assays 
using the H-2D b -restricted E7 49 – 57 CTL peptide 11 to examine 
whether IVAG CpG or PIC also increased functional E7-spe-
cific CD8 T cells and not only tetramer-positive cells. Mice 
were s.c. immunized with the adjuvanted E7 vaccine and PBS, 
PIC, CpG or non-CpG control ODN (2138) was IVAG applied 
5 days later. At day 9, mice were killed and  ex vivo E7-specific 
IFN-  -secreting CD8 T cells were measured in CV ( Figure 4a ) 
and peripheral blood mononuclear cells (PBMCs), spleen, and 
GLN ( Supplementary Table S1 online ) of individual mice. Our 
results show that IVAG application of CpG or PIC enhanced the 
number of E7-specific effector CD8 T cells in the CV (mean E7-
specific IFN-  -secreting CD8 T cells / 10 5 cells ± s.e.m. of 55.2 ± 5.7 
and 35.6 ± 7.1, respectively, as compared with 12.8 ± 2.6 for PBS, 
only significant  P  <  0.001 for CpG). This increase in E7-specific 
IFN-  -secreting cells in the CV is not higher than the increase 
of TetE7   +   CD8   +   T cells, thus suggesting that IVAG CpG or PIC 
does not affect the activation status of the local vaccine-specific 
CD8 T cells. The ELISPOT data also confirm that the effect 
of IVAG CpG or PIC is restricted to the CV as E7-specific 
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IFN-  -secreting CD8 T-cell responses in PBMCs, spleen, and 
GLN were similar to the group of vaccinated mice treated with 
IVAG PBS ( Supplementary Table S1 online ). In addition, E7-
specific IFN-  -secreting cells in CV of mice IVAG treated with 
non-CpG control ODN (15.5 ± 1.2) were similar to PBS-treated 
mice. This suggests that the effect of IVAG CpG does require 
TLR9 ligation by its cognate agonist. 
 Given our hypothesis that systemically vaccine-induced 
CD8 T cells are attracted into the GM upon IVAG application 
of immunostimulants, we suspected that timing of CpG or PIC 
application would be important. Indeed, when IVAG CpG or 
PIC was applied 2 days after E7 vaccination (at a time when 
vaccine-induced CD8 T cells cannot be detected 19 ), E7-spe-
cific CD8 T cells measured at day 9 in the CV of individual 
mice (see  Figure 4b ) were similar to PBS for PIC (7.7 ± 1.8 and 
4 ± 1.5, respectively) and only slightly higher with CpG (22.7 ± 1.5, 
 P  <  0.01, as compared with PBS), but lower than the responses 
measured with IVAG CpG administered at day 6 (55.2 ± 5.7, 
 P  <  0.05). The duration of the effect of one IVAG administration 
of CpG or PIC after E7 vaccination was also evaluated beyond 
day 9 ( Figure 4c ) whereby three groups of mice immunized at 
day 1 with the adjuvanted E7 vaccine, IVAG challenged with 
PBS, CpG, or PIC at day 6, were killed at day 15. The E7-spe-
cific CD8 T-cell responses in CV tissue after IVAG CpG or PIC 
were significantly decreased at day 15 (23.6 ± 4.8 and 23.3 ± 8.7, 
 P  <  0.01 for CpG as compared with day 9 in  Figure 4a ), though 
still higher than IVAG PBS (6.8 ± 1.0,  P  =  not significant). In 
contrast, three consecutive IVAG CpG doses, but not IVAG PIC, 
administered at days 6, 9, and 12 ( Figure 4c ), allowed to sustain 
the E7-specific CD8 T-cell response measured in CV at day 15 
(38.3 ± 4.7 as compared with 42.0 ± 2.3 when measured at day 9 
after a single IVAG CpG administration). Besides, this response 
was higher than that measured at day 15 after PBS, three doses 
of PIC ( P  <  0.01 for both) or one dose of CpG ( P  =  not signifi-
cant). This suggests that three consecutive IVAG CpG instilla-
tions may, at least transiently, maintain a high E7-specific CD8 
T-cell response in CV, while successive PIC applications were 
not beneficial. 
 CD8 T cells expressing both CCR5 and CXCR3 chemokine 
receptors and E-selectin ligands were preferentially 
increased in CV by IVAG CpG 
 To examine the involvement of chemokines and / or endothelial 
addressins upon IVAG CpG recruitment of CD8 T cell in CV, 
we mined the data from a recent study from Lindqvist  et al. 20 
who provided a genome-wide transcriptome analysis of the 
effect of IVAG CpG on the mouse genital tract after 4, 24, and 
48  h. We reasoned that if certain chemokines and / or endothelial 
addressins were associated to a preferential recruitment of CD8 
T cells, the respective receptors / ligands should be increased in 
the array analysis at 24 and / or 48  h. As a control, we first exam-
ined how the T-cell coreceptors were modulated by IVAG CpG 
in the array analysis (see  Supplementary Table S2A online ). 
Interestingly, only the CD8a and b coreceptors, but not the 
CD4, were significantly increased by CpG at 24 and 48  h, in 
agreement with our findings that CD8 T cells, but not CD4 T 
cells, were increased by IVAG CpG at 72  h ( Figure 1 ). We thus 
extracted from the array analysis a list of all the chemokines and 
their respective receptors, as well as addressins / selectins and 
respective ligands / integrins, that were significantly increased 
by IVAG CpG (see  Supplementary Table S2B and C online ). 
To substantiate these observations, the presence of T-cell sur-
face molecules significantly increased at the messenger RNA 
level 24 and / or 48  h after IVAG CpG was then analyzed by flow 
cytometry on the total CD4 and CD8 T cells from the CV of 
vaccinated mice treated with IVAG PBS or CpG. Computing 
the percentage of cells within the CD8 or CD4 T-cell popula-
tions that expressed these chemokine receptors ( Figure 5a ) in 
the presence or absence of IVAG CpG treatment in CV revealed 
a significant increase of CCR5   +   and CXCR3   +   cells among 
CD8 T cells recruited upon IVAG CpG (mean percentage ± 
s.e.m. of 83.2 ± 1.4 and 46.0 ± 1.2, respectively, as compared with 
70.2 ± 3.2 and 35.1 ± 2.7, respectively, after IVAG PBS,  P  <  0.05 
and  P  <  0.01, respectively). In sharp contrast, such increases 
were not observed among CD4 T cells in the IVAG CpG group. 
Interestingly, it was the double-positive CCR5   +   CXCR3   +   cells 
among the CD8 T cells that were significantly increased by CpG 
(26.0 ± 2.1 to 37.9 ± 1.1,  P  <  0.05) and not CD8 T cells express-
ing only one of these chemokine receptors. Moreover, CCR5   +  
was significantly preferentially expressed by CD8 T cells com-
pared with CD4 T cells after IVAG CpG (83.2 ± 1.4 and 63.9 ± 1.5, 
respectively,  P  <  0.01). Among the integrin / selectin ligands 
examined ( Figure 5b ), the percentage of CD8 T cells positive 
for E-selectin ligand   +   (ESL   +   ) was significantly increased by 
CpG (79.5 ± 4.9 as compared with PBS 48.0 ± 5.8,  P  <  0.01), while 
there was no change in the proportion of ESL   +   CD4 T cells. 
Interestingly, IVAG CpG treatment was also associated with a 
significant decreased proportion of   4   +   integrin (mainly   4  1, 
as   4  7-positive cells were fewer and stable) and of PSGL-1   +  
CD8, but not CD4, T cells. In contrast to the T-cell populations 
in CV, expression of chemokine receptors and integrin / selectin 
ligands were less affected by IVAG CpG in the T cells from the 
spleen ( Supplementary Table S3 online ). In addition to the 
IVAG CpG-induced modifications of the CD8 T-cell popula-
tions in the CV, specific T-cell homing programs to the GM 
may add a further level of complexity to the outcomes. Indeed, 
comparison of T-cell populations between spleen, as a surrogate 
of circulating cells, and CV also shows that irrespective of CpG 
treatment, CD4 T cells expressing CCR5   +   , CXCR3   +   , and / or 
CCR2   +   are preferentially recruited to CV, while this is the 
case only for CCR5   +   -expressing CD8 T cells. Concerning the 
integrin / selectin ligands, both CD4 and CD8 T cells express-
ing   L, CD43, ESL, and / or   4 are preferentially recruited to 
CV. However, significant differences between CD4 and CD8 
T cells can also be noticed as more CD4 T cells expressed ESL 
(80.9 ± 2.6 as compared with 48.0 ± 5.8 for CD8 T cells,  P  <  0.01), 
while more CD8 T cells expressed   4 and PSGL-1 (70.3 ± 3.0 and 
50.9 ± 5.0, respectively, as compared with 43.2 ± 3.7 and 20.9 ± 2.7, 
respectively, for CD4 T cells,  P  <  0.001 for both). Altogether, 
these differences in chemokine receptors and integrin / ligands 
expression patterns between CD4 and CD8 T cells both upon 
IVAG CpG and during constitutive homing processes may 
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account, at least in part, for the preferential recruitment after 
IVAG CpG of CD8 T cells in CV. 
 Regression of large genital HPV tumors is enhanced by 
combining s.c. E7 vaccination with three consecutive IVAG 
applications of CpG 
 We recently developed an orthotopic murine model where 
HPV16 E6 / E7-expressing tumors develop in the genital epithe-
lium after an IVAG instillation of luciferase-expressing TC-1 
cells (TC-1-luc). This model more closely mimics the situation 
of women suffering HPV-induced lesions than previous mod-
els involving s.c. injection of tumor cells. 12 Vaccination of mice 
harboring small genital HPV tumors with the adjuvanted E7 
vaccine induced full tumor regression in 90 % of mice; 13 how-
ever, effective regression was not achieved when genital tumors 
were larger. We examined here whether combining vaccination 
with local applications of CpG could enhance tumor regres-
sion, as more E7-specific CD8 T cells would be recruited to CV. 
For this purpose, six groups of 6 – 8 mice IVAG challenged with 
TC-1-luc cells and harboring large tumors at day 12, as shown 
by monitoring bioluminescence with an  in vivo imaging system, 
were used. Mean bioluminescence of tumors was ca. 1.7 × 10 6  p 
  s   −  1  cm   −  2  sr   −  1 in all groups (see  Figure 6a , left panel and one 
representative group of mice in the right panel) and half of these 
mice were s.c immunized with the adjuvanted E7 vaccine and 
the other ones left unvaccinated. One E7-vaccinated group and 
one control group then received one IVAG dose of CpG 5 days 
after immunization (at day 17) while two other groups were 
treated with three consecutive IVAG applications of CpG every 
3 days (at days 17, 20, and 23). Percentages of survival upon time 
( Figure 6b ) are shown for each group. Significant extension of 
survival relative to control untreated mice was only observed 
in mice receiving E7 vaccination followed by IVAG treatment 
with either one or three applications of CpG ( P  =  0.0036 and 
 P  =  0.0004, respectively, using adjusted log-rank tests). This 
was confirmed in independent experiments and by analysis of 
the compiled data ( Figure 6c ): 5 / 10 mice and 9 / 12 mice were 
tumor free at 100 days after E7 vaccination followed by one or 
three IVAG CpG, respectively, as compared with 0 / 13 untreated 
mice ( P  =  0.0075 and  P  =  0.0001, respectively, using Fisher ’ s exact 
test). Our data further showed that the number of tumor-free 
mice in the E7-vaccinated and IVAG treated with three CpG 
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 Figure 5   Expression of chemokine receptors and integrin / selectin ligands in the T cells from cervix-vagina (CV) upon intravaginal (IVAG) CpG. 
Groups of eight mice were subcutaneously immunized with the adjuvanted E7 vaccine, and 5 days later IVAG instilled with phosphate-buffered saline 
(PBS) (white symbols) or CpG (black symbols). Mice were killed 3 days later, at day 9, and flow cytometry staining and analysis were performed on 
cells recovered from pools of two CV. Dead cells were excluded with the aqua dead kit. The percentage of total CD4 (circle) or CD8 (triangle) T cells 
expressing the chemokine receptors CXCR3, CCR5, CCR2, and CCR7 ( a ) and integrin / selectin ligands:   L,   4,   4  7,  L -selectin, PSGL-1, CD43, ESL, 
and PSL ( b ) among either total CD4 or CD8 T cells are shown. The horizontal bars represent the mean percentages. Data are representative of results 
obtained in two independent experiments. Significant differences between IVAG PBS and IVAG CpG treatments within each T-cell populations as well 
as between the CD4 and CD8 T cells upon IVAG PBS are indicated by  * P  <  0.05,  * * P  <  0.01, and  * * * P  <  0.001. 
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applications group was significantly higher as compared with 
the only E7-vaccinated mice (9 / 12 as compared with 3 / 16 mice, 
 P  =  0.0061 using Fisher ’ s exact test). Interestingly, three IVAG 
CpG applications in the absence of E7 vaccination, as well as 
E7 vaccination alone, also slightly increased survival of mice as 
compared with untreated mice ( P  =  0.0047 for both, following 
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 Figure 6   Genital tumor regression upon subcutaneous (s.c.) E7 vaccination followed by intravaginal (IVAG) CpG. Six groups of 6 – 8 mice were 
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non-adjusted log-rank tests), though no statistical difference 
was observed when assessing the number of tumor-free mice 
at the end of the assay. In fact, ca. 50 % of the mice were already 
dead before the third IVAG CpG application in the absence of 
vaccination. 
 To further examine the involvement of CD8 T cells on the 
IVAG CpG anti-tumor effect, we determined the effect of 
antibody-mediated CD8 or CD4 T-cell depletion started 24  h 
before the first IVAG CpG application and maintained until 
day 55 ( Figure 7 ). Vaccination followed by three IVAG CpG 
applications significantly regressed these large genital tumors 
( P  =  0.0098, as compared with untreated mice, using adjusted 
log-rank test), an effect that was significantly diminished by 
CD8 T-cell depletion ( P  =  0.0123), but left intact by CD4 T-cell 
depletion. This confirms that CD8 T cells are the mediators of 
the IVAG CpG antitumor effect. In summary, three consecu-
tive IVAG applications of CpG represent an additional powerful 
benefit to E7 vaccination for inducing regression of large genital 
HPV tumors in mice. 
 DISCUSSION 
 In this study, we demonstrated that IVAG application of CpG or 
PIC 5 days after parenteral immunization with a long HPV16 
E7 synthetic peptide and adjuvants in mice led to a major 
increase of the vaccine-specific CD8 T-cell selectively in the GM. 
Furthermore, therapeutic E7 vaccination followed by repeated 
IVAG CpG applications led to the regression of large genital 
HPV tumors in 75 % of mice, while only 20 % regression was 
obtained in mice receiving vaccination alone. 
 Both CpG and PIC are synthetic compounds able to mimic 
the immune stimulatory activity of microbial DNA and dou-
ble-stranded RNA, respectively. They were previously shown 
to be effective adjuvants for protein-based vaccines, mediating 
maturation of, and cytokine secretion by, dendritic cells (DCs), 
leading to enhanced antigen presentation, polarization of T-cell 
responses, and reversal of suppressive regulatory T cell activity. 21 
Topical application of CpG and / or PIC were also reported to 
induce cytokine and chemokine secretion leading to attraction 
of DC and natural killer cells 22 or macrophages 23 in mouse lung, 
DC, and natural killer cells in mouse GM 24 or T cells (both CD4 
and CD8) in human skin. 25 To our knowledge, however, this 
is the first report where preferential attraction of either total 
or vaccine-specific CD8 T cells over CD4 T cells was induced 
at the site (in our case, the GM) of CpG or PIC application. 
Importantly, our data demonstrate that this activity is medi-
ated by the well-described signaling pathways for CpG and PIC. 
Indeed, the previously described effects of CpG involve the direct 
ligation of TLR9, 17 while ODNs devoid of the CpG motifs fail to 
engage TLR9 and deliver the innate response signaling, 18 as also 
shown in our experiments ( Figure 4a ). PIC can signal through 
two main sensors, i.e., TLR3 in the endosomes 14 or Mda5, an 
RNA helicase present in the cytoplasm. 15 Our results in mice 
deficient for Trif (an adaptor downstream TLR3), Cardif (an 
adaptor downstream Mda5), or both demonstrated that IVAG 
PIC after E7 vaccination can attract CD8 T cells into the GM by 
either one of the two pathways. A third sensor or pathway could 
be further excluded as neither attraction of E7-specific nor total 
CD8 T cells could be observed in double-KO Trif – Cardif mice. 
The redundancy of Trif and Cardif for PIC applied locally is 
in line with data indicating that the two downstream signaling 
pathways result in activation of a similar array of transcription 
factors (i.e., IRF3, JUN, ATF2, and NF  B) leading to the induc-
tion of similar genes (reviewed in ref.  26). However, our findings 
stand in contrast to the required cooperation between the two 
pathways observed by Kumar  et al. 27 when PIC was used as 
adjuvant in systemic administration. 
 As CpG and PIC act through different TLR signaling pathways 
(MyD88-dependent (D) and MyD88-independent (I), respec-
tively), one might hypothesize that a synergistic effect could 
result in higher numbers of attracted total or vaccine-specific 
CD8 T cells when IVAG CpG and PIC would be administered 
together. In this regard, Bagchi  et al. 28 showed that D and I ago-
nists (including CpG and PIC) were markedly synergistic in 
inducing cytokine production  in vivo in mice, while D-specific 
agonists induced tolerance to one another. However, in contrast 
to these data, obtained a few hours after systemic use of CpG and 
PIC, simultaneous administration of IVAG CpG and PIC did not 
attract higher numbers of either total or E7-specific CD8 T cells 
in CV than the single molecules. This difference may be owing 
to the IVAG route of administration and / or to the different and 
longer experimental readout in our case. Indeed, the effect of 
PIC on cytokines / chemokines secretion was shown to only occur 
at short term and with no additive effect when applying succes-
sive doses, in contrast to CpG. 29 This may also explain the inef-
fectiveness of successive IVAG PIC doses in our experiments. 
Chemokines have a key role in innate inflammatory responses 
leading to recruitment of circulating leukocytes, including T 
cells, to sites of inflammation. 7 In mice, IVAG administration 
of CpG stimulates a potent response of MIP-1  (CCL3), MIP-
1  (CCL4), MIP-2, IP-10 (CXCL10), and RANTES (CCL5) 
chemo kines in the vagina and / or GLN. 10 However, additional 
mechanisms by which CpG may contribute to CD8 T-cell attrac-
tion to the GM may include induction of adhesion molecules. 
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In this regard, CpG was shown to upregulate ICAM-1 and 
E-selectin in endothelial cells. 30 Upon bacterial 31 or viral 32 
infections, lymphocyte trafficking to the GM may involve 
both mucosal and non-mucosal homing interactions, and both 
mucosal adhesion molecule, MadCAM-1, 33 and non-mucosal 
adhesion molecules (ICAM-1, VCAM-1, and E-selectin), sug-
gesting that direct induction of these adhesion molecules in 
the GM by CpG may also occur. Indeed, this was confirmed in 
a genome-wide transcriptome report 20 and in our analysis of 
these data ( Supplementary Table S2 online ). Our flow cytom-
etry analysis of chemokine receptors expressed upon IVAG CpG 
by total T cells in the GM highlighted a population of CD8 T 
cells that expressed both CCR5 and CXCR3, and thus would be 
expected to preferentially accumulate in the CV through inter-
action with the CpG-induced CCL5, CCL3, CCL4, CXCL9, 
CXCL10, and / or CXCL11. Upon IVAG CpG treatement, these 
CD8 T cells also exhibited a combination of high expression of 
ESL (as determined by direct detection of cell-bound recom-
binant E-selectin) and low expression of   4 and PSGL-1. ESLs 
include PSGL-1, but also CD43 (highly expressed by both CD4 
and CD8 T cells in CV,  Figure 5b ) and others, with physiological 
binding to selectin dependent on the type of glycosylation and / or 
interactions with other integrins or chemokines. 34 Interestingly, 
a combination of both CCR5 and CXCR3 35 or E-selectin 31 was 
also required for pathogen-specific CD4 T-cell recruitment 
in GM after genital infection by Chlamydia. However, to our 
knowledge, our study is the first to report on preferential recruit-
ment of total CD8 T cells over CD4 T cells, as well as on differ-
ences in expression of homing molecules between CD4 and CD8 
T cell in the GM or in other mucosae / tissues. Both differential 
expression of chemokine receptors and of selectin ligands may 
account for the preferential recruitment of CD8 T cells upon 
IVAG CpG. However, further investigations will be required to 
unravel the precise mechanisms involved. 
 Immunization followed by IVAG CpG to attract systemically 
induced vaccine-specific CD8 T cells to the tumor site turned 
out to be an effective strategy for inducing regression of large 
already established HPV-associated genital tumors in a murine 
orthotopic model ( Figure 7 ). Our strategy differ from previ-
ous cancer immunotherapies, whose rationale for CpG, PIC, 
or other TLR agonists, beside their use as cancer-vaccine adju-
vants, has primarily focused on their ability to increase the anti-
gen-presenting function of DC, 36,37 thereby directly enhancing 
tumor-specific CTL responses when used alone 38 – 40 or in com-
bination with chemotherapy, 41 topical skin-bleaching agent, 42 
radiotherapy, 43 cryosurgery, 44 or vaccination. 45 We expect that 
our strategy may be extended to tumors located in other mucosal 
sites, as preliminary data (not shown) suggest that intravesical 
instillation of CpG after parenteral vaccination similarly results 
in increased vaccine-specific CD8 T cells in the bladder. 
 Induction of innate immune responses to counteract the 
tumor environment was also shown to be especially beneficial 
in the treatment of tumors located in the GM. This mucosa 
normally maintains a rather immunosuppressive environment 
that accommodates commensal bacteria and is permissive for 
fecundation and implantation of the semi-allogeneic embryo. 
This situation favors the development of high-grade lesions 
and / or cervical cancer after HPV infections, and is correlated 
with local type II cytokines, absence of IFN-  , reduced density 
and functions of Langerhans cells, 46 and an increased propor-
tion of regulatory T cells in the draining LN in cervical cancer 
cases. 47 Interestingly, in the case of vulvar intraepithelial neopla-
sia, it was recently shown that local long-term treatment with the 
immune modifier Aldara (a TLR7 / 8 agonist) before parenteral 
vaccination was associated with a higher infiltration of effec-
tor T cells in responding lesions. 48 In our setting, the repetitive 
application of IVAG CpG alone also slowed genital tumor pro-
gression, although tumor-free mice were rarely observed with 
such aggressively growing tumors. Only the combination of 
vaccination with IVAG CpG resulted in efficient genital tumor 
regression. 
 In conclusion, our study provides an outline for future 
clinical investigations for eradicating HPV-induced intraepi-
thelial neoplasia or other tumors located in mucosae involving 
a combination of antigen-specific adaptive immunity followed 
by the induction of non-specific local innate immunity to 
promote infiltration of antigen-specific CTL to eradicate the 
lesions. 
 METHODS 
 Immunization of mice .  Eight-week-old female C57BL / 6 wild-type 
mice (Charles River, L ’ Arbresle, France), Trif KO, Cardif KO, and Trif-
Cardif double-KO mice (kindly provided by Professor J. Tschopp and 
Aubry Tardivel, Institute of Biochemistry, University of Lausanne, 
Switzerland (UNIL)) were used following ethical directives of the Swiss 
veterinary authorities. The E7 1 – 98 , E7 34 – 98 , and E7 49 – 57 peptides 11 were 
chemically synthesized by the Protein and Peptide Chemistry Facility 
of the Institute of Biochemistry (UNIL, Switzerland). Either E7 1 – 98 or 
E7 34 – 98 (referred thereafter as E7) was used for immunizations as both 
induced similar E7-specific responses in all organs examined. 13 Mice 
were synchronized in a diestrus-like status by a s.c. injection with 0.1   g 
  -estradiol and 24  h later with 2  mg DepoProvera (Pfizer AG, Zurich, 
Switzerland). The E7 polypeptide (50   g) in combination with the 
heat-labile enterotoxin HLT 49 (0.4   g per dose, Berna-Biotech, Bern, 
Switzerland) and CpG ( # 1826 (5  -TCCATGACGTTCCTGACGTT-
3  ), Coley Pharmaceutical Group, Wellesley, MA, 10   g per dose) were 
injected s.c. at the base of the tail. PIC (100   g per dose, Sigma, Buchs, 
Switzerland or Invivogen, Toulouse, France) or CpG ( # 1826 or  # 2138 
(5  -TCCATGAGCTTCCTGAGCTT-3  ), Coley Pharmaceutical Group, 
100   g per dose) were instilled (10   l volume) using a micro pipet tip in 
the vagina of deeply anesthetized mice. 
 Preparation of PBMCs, splenocytes, GLN, CV cells, and bone-
marrow-derived DCs .  PBMCs were prepared from tail blood. 19 Single-
cell suspensions of spleen and GLN (ileo-sacral lymph nodes draining 
the CV) were obtained by mechanical dissociation. 19 The uterine horns 
were removed from the genital tract, and CV was minced and digested 
step wise with 0.5  mg  ml   −  1 thermolysin (Roche, Basel, Switzerland), 
1  mg  ml   −  1 collagenase / dispase (Roche), and 2  mg  ml   −  1 DNase 
(Sigma). 19 Bone-marrow-derived DCs were generated in the presence 
of 150  U  ml   −  1 of recombinant mouse granulocyte – macrophage colony-
stimulating factor (R & D Systems, Abingdon, UK). 13 
 IFN- γ ELISPOT assay .  IFN-  ELISPOT assay was performed as 
described in detail in ref.  19. Briefly, 30,000 bone-marrow-derived DCs 
per well were loaded with 1   g  ml   −  1 of E7 49 – 57 peptide or medium alone 
(control wells) for 1  h before adding 100,000 CV cells per well. After 
16 – 24  h, E7-specific responses were defined for each individual mouse 
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as the number of IFN-  spots per 10 5 cells in the E7-stimulated wells 
minus the number of IFN-  spots per 10 5 cells in the control wells. 
The threshold of significance was calculated as the mean   +  3 s.d. of the 
E7-specific responses of five naive mice, and corresponded to three spots 
per 10 5 cells in the spleen and GLN samples and two spots per 10 5 cells 
in PBMC and CV samples. 
 Fluorescent tetramer and T-cell labeling .  Phycoerythrin (PE)-con-
jugated E7 49 – 57 and L1 165 – 173 H-2D b -restricted tetramers (TetE7 and 
TetL1, respectively, from Ludwig Institute for Cancer Research tetramer 
production facility, Epalinges, Switzerland) and allophycocyanine 
(APC)-labeled CD8a (clone 53-6.7, eBioscience, Vienna, Austria) stain-
ings were performed as previously described. 11 TetE7   +   CD8   +   T percent-
ages within total cells were calculated after subtraction of the background 
measured with control TetL1. CD4 labeling was performed using fluo-
rescein isothiocyanate-conjugated anti-CD4 antibodies (clone GK1.5, 
eBioscience). Cells were analyzed using FACS Calibur and CellQuest Pro 
software (BD Biosciences, Allschwil, Switzerland). Staining for chemo-
kines and / or integrins / selectins ligands was performed using a 10-color 
flow cytometry protocol. Stained cells were acquired on a Gallios Flow 
Cytometer (Beckman Coulter, Nyon, Switzerland) and the multidimen-
sional fluorescence data were analyzed with the FlowJo software (Tree 
Star, Ashland, OR). The monoclonal anti-mouse antibodies used were: 
PE / TXRD-anti-CD45 / LCA (I3 / 2.3), PE / TXRD-anti-CD8a (53-6.7), PE-
Cy7anti-  L (I21 / 7) (Southern Biotech, Birmingham, AL); PerCPCy5.5-
anti-CD3 (17A2), PerCPCy5.5-anti-CD43 (1B11), APC-Cy7-anti-CD8a, 
AlexaFluor700-anti-CD4 (GK1.5), AlexaFluor488-anti-  4 (R1-2), 
AlexaFluor488-anti-CCR5 (HM-CCR5), APC-anti-  4  7 (DATK32), 
PacificBlue-anti- L -selectin (MEL-14), and PE-Cy7-CXCR3 (CXCR3-173) 
(Biolegend, London, UK); APC- or PE-Cy7-anti-CD8a (53-6.7), eF450-
anti-CD4 (GK1.5), and AlexaFluor700-anti-CCR7 (4B12) (eBioscience); 
PE-anti-PSGL-1 (2PH1, BD Biosciences); and APC-anti-CCR2 (475301) 
(R & D Systems). For staining ESL and PSL, cells were incublated with 2   g 
of E-selectin / human IgG-Fc chimera or 0.1   g of P-selectin / human IgG-
Fc chimera, respectively, (R & D Systems), in 50   l Hank ’ s Balanced Salt 
Solution (Gibco, Life Technologies, Zug, Switzerland) containing 0.2 % 
bovine serum albumin (Sigma), before the other extracellular stainings. 
Selectin chimeras were detected with an AlexaFluor647-anti-human IgG, 
FC  (Jackson Immunoresearch, Suffolk, UK). Dead cells were stained with 
a live / dead fixable aqua dead cell stain kit (Invitrogen, Life Technologies). 
 Challenge of mice with tumor cells .  The TC-1 cell line (C57BL / 6 pri-
mary lung epithelial cells transduced with retroviral vectors expressing 
HPV16 E6 / E7 and activated c-Ha-ras) was kindly provided by Professor 
T.-C. Wu (Johns Hopkins Medical Institutions, Baltimore, MD) and fur-
ther transduced with a luciferase-expressing lentiviral vector to generate 
TC-1-luc cells. 12 Anesthetized diestrus synchronized mice were IVAG pre-
treated with 4 % nonoxynol-9 (N9, Igepal, Sigma) for 6  h, washed with PBS, 
and IVAG challenged with 20,000 TC-1-luc cells. Genital tumor growth 
was monitored by bioluminescence 15  min after an intraperitoneal injec-
tion of  D -luciferin (Promega, D ü bendorf, Switzerland, 150   g  g   −  1 of  body 
weight) in a Xenogen imaging system (IVIS lumina, Xenogen / Caliper Life 
Science, kindly provided by Cellular Imaging Facility, UNIL, Lausanne). 
 In vivo T-cell depletion .  Monoclonal rat anti-CD8 and anti-CD4 IgG 
antibodies 11 were purified from GK1.5. and 2.43 rat hybridomas (kindly 
provided by Dr Martin Kast, University of Southern California, Los 
Angeles, CA). One hundred microgram of anti-CD8 antibody or 200   g 
of anti-CD4 antibody were intraperitoneally injected every 6 days to 
maintain close to 100 % cell depletion in spleen, PBMCs, and GLN as 
examined by flow cytometry in pilot experiments. Specific cell deple-
tions were further assessed in PBMCs from mice bled during the tumor 
protection assay. 
 Statistical analysis .  Statistical analyses were performed using 
Prism 5.00 for Windows (GraphPad software, San Diego, CA). Multiple 
comparisons were performed using Kruskal – Wallis or one-way analysis 
of variance followed by a Dunn ’ s or Tukey ’ s  post-hoc test, respectively. 
Other statistical tests are indicated in the text or figure legends. 
 SUPPLEMENTARY MATERIAL is linked to the online version of the 
paper at  http://www.nature.com/mi 
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